Drug Immunogenicity Evaluation – Accredited ADA, Neutralizing Antibody and Cellular Response Testing for Global Biopharmaceutical Markets
Our internationally accredited laboratory delivers a comprehensive evaluation of drug immunogenicity service that enables pharmaceutical developers, biotechnology companies, contract research organisations and biosimilar manufacturers worldwide to assess the unwanted immune responses that therapeutic proteins, monoclonal antibodies, gene‑therapy vectors and cell‑based products may provoke in patients. Every investigation is conducted under the rigorous framework of ISO/IEC 17025, and each report bearing the ILAC mark is unconditionally accepted by regulatory authorities, notified bodies and supply‑chain partners in all major economies. The evaluation of drug immunogenicity employs a multi‑tiered testing strategy harmonised with the FDA Guidance for Industry on Immunogenicity Assessment, the EMA Guideline on Immunogenicity of Therapeutic Proteins, and the USP General Chapters ⟨1106⟩ and ⟨1032⟩, combining sensitive bridging and direct‑format enzyme‑linked immunosorbent assays, electrochemiluminescence platforms, cell‑based neutralizing‑antibody bioassays, and multiparameter flow‑cytometry for the characterization of the underlying T‑cell reactivity. For a sponsor submitting a Biologics License Application, a biosimilar developer demonstrating the similarity of the immunogenicity profile, or a clinical‑stage company investigating an unexpected loss of efficacy, this service provides the legally robust, defensible data that underpin the risk‑management plan, the labelling negotiation and the demonstration of the benefit‑risk balance of the therapeutic product.
Product Samples We Regularly Subject to Drug Immunogenicity Evaluation
The sample‑receipt, processing and long‑term storage facilities in our laboratory accommodate the clinical and the non‑clinical matrices that are the source of the anti‑drug‑antibody response. The following categories represent the most frequently tested items:
- Human and animal serum and plasma – the serial samples collected during the preclinical toxicology studies, the phase I–III clinical trials and the post‑marketing surveillance, tested for the binding and the neutralizing anti‑drug antibodies according to the protocol‑defined sampling schedule
- Cerebrospinal fluid, synovial fluid and other compartmental fluids – the samples from the special populations or the specific routes of administration where the local immunogenicity may differ from the systemic response
- Peripheral blood mononuclear cells and the isolated T‑cell populations – the cells obtained from the whole blood by the density‑gradient centrifugation, used for the T‑cell proliferation, the cytokine‑release and the activation‑marker assays that characterize the cellular arm of the immune response
- Therapeutic protein drug substances and the formulated drug products – the monoclonal antibodies, the Fc‑fusion proteins, the enzyme‑replacement therapies, the bispecific antibodies, the antibody‑drug conjugates and the gene‑therapy vectors that are the subject of the immunogenicity assessment
- Biosimilar and the reference‑listed products – the side‑by‑side immunogenicity comparison samples that are generated during the biosimilarity exercise, evaluated for the relative incidence and the magnitude of the anti‑drug‑antibody response
- Stressed, degraded and the process‑change samples – the drug‑product batches that have been subjected to the forced degradation, the temperature excursion or the manufacturing‑process modification, tested to determine whether the structural alteration increases the immunogenicity risk
Anti‑Drug Antibody (ADA) Screening, Confirmatory and Titration Assays – Core Evaluation of Drug Immunogenicity According to USP ⟨1106⟩ and the EMA Guideline
- Sensitive bridging‑format and the direct‑format enzyme‑linked immunosorbent assay or the electrochemiluminescence screening according to the internal validated protocol aligned with the USP General Chapter ⟨1106⟩ (Immunogenicity Assays – Design and Validation of Assays to Detect Anti‑Drug Antibodies) and the FDA/EMA immunogenicity guidelines: the test sample is incubated with the drug molecule that is immobilised on the microtitre plate or is labelled with the ruthenium chelate for the electrochemiluminescence detection, and the captured anti‑drug antibodies are detected with a second, labelled drug molecule or an anti‑species immunoglobulin‑reagent. The signal‑to‑noise ratio or the relative‑luminescence‑unit value is calculated, and the screening‑cut‑point that provides a 5 % false‑positive rate is established during the validation. The sample is reported as “screen‑positive” or “screen‑negative”, and the screen‑positive samples proceed to the confirmatory assay. This evaluation of drug immunogenicity provides the first‑tier, high‑throughput detection of the binding anti‑drug antibodies, which is the mandatory primary endpoint of every clinical‑trial immunogenicity assessment.
- Confirmatory and the competitive‑inhibition assay for the demonstration of the drug‑specificity: the screen‑positive sample is re‑tested in the presence of an excess of the unlabelled drug and in the presence of an irrelevant control protein. A reduction in the signal of at least a pre‑defined threshold – typically 30 % to 50 % – confirms that the detected antibody is specific for the drug, distinguishing the true anti‑drug antibody from the non‑specific, the rheumatoid‑factor‑like or the heterophilic‑antibody interference. The confirmatory‑cut‑point and the percentage‑inhibition criteria are pre‑validated according to the regulatory expectations.
- Endpoint‑titre and the semi‑quantitative titre determination by the serial‑dilution method: the confirmed‑positive sample is serially diluted and re‑assayed, and the titre – the highest dilution factor that still yields a positive result – is reported, providing the semi‑quantitative measure of the magnitude of the anti‑drug‑antibody response that can be correlated with the clinical pharmacokinetics, the efficacy and the adverse‑event data.
- Domain‑specific and the multi‑epitope ADA characterisation: for the multi‑domain therapeutics such as the bispecific antibodies and the Fc‑fusion proteins, the screening and the confirmatory assays are performed using the individual domains or the subunits as the capture and the detection reagents, and the domain‑specificity of the anti‑drug antibody response is mapped, providing the mechanistic insight into whether the immune response is directed against the antigen‑binding site, the Fc region or the linker.
- Drug‑tolerance and the acid‑dissociation pre‑treatment: for the therapeutic proteins that are dosed at the high concentrations and that have a long serum half‑life, the sample is pre‑treated with the acid to dissociate the pre‑existing drug–ADA immune complexes, and the freed ADA is then captured and detected, improving the sensitivity and the accuracy of the assay in the presence of the high circulating drug levels, which is a common regulatory requirement for the monoclonal‑antibody drugs.
Neutralizing Antibody Bioassays – Cell‑Based and Competitive‑Ligand‑Binding Evaluation of Drug Immunogenicity
- Cell‑based neutralizing‑antibody assay using the drug‑responsive reporter‑gene cell line according to the internal validated protocol: a cell line that expresses the drug target and that responds to the drug with a measurable signal – such as the luciferase expression under the control of a drug‑responsive promoter, the phosphorylation of a signalling protein, or the inhibition of the cell proliferation – is incubated with a fixed concentration of the drug and the serial dilutions of the test serum. The reduction of the drug‑induced signal in the presence of the serum, relative to the drug‑alone control, indicates the presence of the neutralizing antibodies that block the pharmacological activity of the drug. The neutralizing‑antibody titre – the reciprocal of the dilution that causes a 50 % inhibition of the drug response – is reported, and the assay sensitivity and the drug tolerance are validated according to the FDA and the EMA recommendations. This evaluation of drug immunogenicity provides the direct, functional evidence of the capacity of the patient’s immune response to abrogate the therapeutic effect, which is the most clinically relevant immunogenicity endpoint.
- Competitive‑ligand‑binding neutralizing‑antibody assay: for the drugs that act by binding to a soluble ligand, the serum is incubated with the drug and the labelled‑ligand, and the inhibition of the drug‑ligand binding by the serum antibodies is measured by the ELISA or the electrochemiluminescence, providing the alternative, non‑cell‑based neutralizing‑antibody detection that is often more robust and easier to transfer between the laboratories.
- Viral‑ or the gene‑therapy‑vector neutralizing‑antibody assay: for the adeno‑associated‑virus or the adenoviral‑vector‑based gene therapies, the test serum is incubated with the reporter‑vector, and the reduction of the transduction efficiency in a permissive cell line is quantified by the luciferase or the green‑fluorescent‑protein expression, measuring the pre‑existing and the treatment‑induced neutralizing antibodies that can prevent the successful gene delivery.
- Correlation of the neutralizing‑antibody titre with the clinical pharmacokinetics and the pharmacodynamics: the neutralizing‑antibody data are plotted against the drug‑trough‑concentration, the biomarker‑response and the clinical‑efficacy scores of the individual patients, and the correlation coefficient and the exposure‑response relationship are reported, providing the integrated immunogenicity‑clinical‑response analysis that the regulatory agencies expect for the benefit‑risk assessment.
Immunophenotyping, T‑Cell Reactivity and Cytokine Profiling – Cellular Evaluation of Drug Immunogenicity for the Mechanistic Understanding
- T‑cell proliferation and the activation‑marker assay by the flow cytometry according to the internal validated protocol: the peripheral blood mononuclear cells from the treated subjects or the healthy‑donor volunteers are labelled with the carboxyfluorescein succinimidyl ester and incubated with the drug or the overlapping peptide libraries that span the drug sequence, and the proliferation of the CD4⁺ and the CD8⁺ T‑cells, and the expression of the activation markers such as the CD25, the CD69 and the CD71, are measured by the multiparameter flow cytometry. The stimulation index and the percentage of the proliferated cells are reported, providing the direct evidence of the drug‑specific T‑cell reactivity that underpins the anti‑drug‑antibody formation.
- Cytokine‑release and the cytokine‑secretion‑profiling assay: the drug‑stimulated peripheral‑blood‑mononuclear‑cell culture supernatant is analysed by the multiplex bead‑based immunoassay or the ELISpot for the concentrations of the interleukin‑2, the interferon‑γ, the interleukin‑4, the interleukin‑5, the interleukin‑10, the interleukin‑17 and the tumour‑necrosis‑factor‑α, and the cytokine‑release profile is used to classify the immune response as a Th1‑, a Th2‑ or a Th17‑biased response, which is predictive of the class‑switching, the IgE‑mediated hypersensitivity and the neutralizing‑antibody development.
- Major‑histocompatibility‑complex‑associated peptide‑proteomics and the in‑silico immunogenicity prediction: the drug is digested, and the peptides that are eluted from the major‑histocompatibility‑complex class II molecules of the antigen‑presenting cells are identified by the liquid‑chromatography–tandem‑mass‑spectrometry, and the experimentally verified T‑cell epitopes are compared with the predictions of the in‑silico algorithms, providing the data that the protein‑engineering team uses to de‑immunize the drug by the targeted mutation of the immunodominant epitopes. This evaluation of drug immunogenicity integrates the experimental and the computational approaches for the development of the next‑generation, low‑immunogenicity biotherapeutics.
- Baseline and the treatment‑emergent immunogenicity comparison: the pre‑treatment, the on‑treatment and the follow‑up samples are analysed for the ADA, the neutralizing‑antibody and the T‑cell parameters, and the incidence of the treatment‑emergent immunogenicity – the antibodies that appear or increase in the titre after the drug administration – is calculated, providing the regulatory‑reportable metric that is summarised in the product label and the risk‑management plan.
Report Acceptance and Global Regulatory Compliance
All investigations performed within our evaluation of drug immunogenicity are executed under the fully accredited scope of our ISO/IEC 17025 quality management system. Each test report that carries the ILAC mark is therefore automatically recognised by regulatory authorities, notified bodies, customs offices and supply‑chain partners in all major economies. For pharmaceutical developers, biotechnology companies, biosimilar manufacturers and contract‑research organisations anywhere in the world, the report constitutes legally robust, internationally accepted evidence that the anti‑drug‑antibody incidence and titre, the neutralizing‑antibody activity, the T‑cell reactivity and the cytokine‑release profile have been determined in accordance with the applicable FDA, EMA, USP and customer‑specified guidelines. The documentation can be directly used to support the Biologics License Application, the Marketing Authorisation Application, the biosimilar‑comparability demonstration, the issue of inspection certificates according to EN 10204 or equivalent national standards, and the resolution of commercial and technical disputes concerning the immunogenicity risk and the immune‑mediated adverse events of any therapeutic protein, gene‑therapy vector or cell‑based product.
